Taken together, these results show that increased ROS in response to loss of TIGAR can promote a mesenchymal shift accompanied by increased invasive capacity, but that modulating ROS levels can allow the tumor cells to toggle between the two phenotypes. This evidence concerns the gene TIGAR and neoplasm.